Skip to main content
. 2019 Nov 1;4(21):e131028. doi: 10.1172/jci.insight.131028

Figure 5. Administration of anti-CD25 ablates, and rapamycin enhances, the protective potential of intragraft A20 expression.

Figure 5

(A) Percent of mice normoglycemic following the transplantation of 300 BALB/c islet expressing GFP or A20 (MOI 10:1) and transplanted under the kidney capsule of allogeneic C57BL/6 recipients. Recipient mice were administered 200 μg αCD25, clone PC61 (PC61-GFP, n = 2; PC61-A20, n = 6) or an isotype control (Iso-GFP, n = 10; Iso-A20, n = 7) on day 0 and every 10 days thereafter (Supplemental Figure 3). (B) Percent of C57BL/6 mice normoglycemic after receiving allogeneic BALB/c islet grafts transduced with GFP or A20 and administered a low dose of rapamycin (0.1 mg/kg at day of transplantation and every day thereafter for 7 days, plus RAPA, n = 7; GFP plus RAPA, n = 5) or no rapamycin (A20, n = 7; GFP, n = 5). Data is cumulative over 3 independent experiments. Significance determined by Log-rank test; *P < 0.05; **P < 0.01.